Regeneron Pharmaceuticals, Inc. Share Price
Equities
REGN
US75886F1075
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
973.8 USD | +0.60% | +1.76% | +10.87% |
Sales 2024 * | 13.85B 1,106B | Sales 2025 * | 14.95B 1,194B | Capitalization | 105B 8,391B |
---|---|---|---|---|---|
Net income 2024 * | 4.06B 324B | Net income 2025 * | 4.47B 357B | EV / Sales 2024 * | 6.93 x |
Net cash position 2024 * | 9.06B 724B | Net cash position 2025 * | 14.79B 1,181B | EV / Sales 2025 * | 6.04 x |
P/E ratio 2024 * |
27.6
x | P/E ratio 2025 * |
24.9
x | Employees | 13,677 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.34% |
Latest transcript on Regeneron Pharmaceuticals, Inc.
1 day | +0.60% | ||
1 week | +1.76% | ||
Current month | +9.33% | ||
1 month | +4.02% | ||
3 months | +2.14% | ||
6 months | +21.89% | ||
Current year | +10.87% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 64 | 07/01/88 | |
Chief Executive Officer | 71 | 07/01/88 | |
Director of Finance/CFO | 54 | 31/12/02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 11/11/10 |
Chief Executive Officer | 71 | 07/01/88 | |
Michael Brown
BRD | Director/Board Member | 82 | 31/05/91 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.27% | 0 M€ | 0.00% | - | |
7.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
10/05/24 | 973.8 | +0.60% | 351,356 |
09/05/24 | 968 | +1.28% | 281,949 |
08/05/24 | 955.8 | -1.46% | 424,925 |
07/05/24 | 970 | +1.18% | 362,320 |
06/05/24 | 958.6 | +0.17% | 352,000 |
Delayed Quote Nasdaq, May 10, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.87% | 105B | |
+3.91% | 109B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B | |
+295.70% | 8.12B |
- Stock Market
- Equities
- REGN Stock